Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Hammond

Showing results (431-440 of 448) with videos related to

Pageof 45
Sort By:
Plant Physiology|April 8, 2021
Magnesium and calcium overaccumulate in the leaves of a schengen3 mutant of Brassica rapaThomas D Alcock, Catherine L Thomas, Seosamh Ó Lochlainn, et al.
The Journal of Antimicrobial Chemotherapy|October 14, 2017
Pharmacokinetics and safety results from the Phase 3 randomized, open-label, study of intravenous posaconazole in patients at risk of invasive fungal diseaseOliver A Cornely, Michael N Robertson, Shariq Haider, et al.
The Journal of Antimicrobial Chemotherapy|September 30, 2017
Pharmacokinetics and safety results from the Phase 3 randomized, open-label, study of intravenous posaconazole in patients at risk of invasive fungal diseaseOliver A Cornely, Michael N Robertson, Shariq Haider, et al.
New Microbes and New Infections|September 2, 2025
An open-label phase II trial of sotrovimab (VIR-7831) prophylaxis against COVID-19 infection in immunocompromised individuals with impaired SARS-CoV-2 humoral immunityIsabel H Gonzalez-Bocco, Rayven Frierson, Alyssa Cho, et al.
The Plant Cell|January 10, 2012
Analyzing lateral root development: how to move forwardIve De Smet, Philip J White, A Glyn Bengough, et al.
Annals of Internal Medicine|November 13, 2023
SARS-CoV-2 Virologic Rebound With Nirmatrelvir-Ritonavir Therapy : An Observational StudyGregory E Edelstein, Julie Boucau, Rockib Uddin, et al.
Medrxiv : the Preprint Server for Health Sciences|July 10, 2023
SARS-CoV-2 virologic rebound with nirmatrelvir-ritonavir therapyGregory E Edelstein, Julie Boucau, Rockib Uddin, et al.
The Plant Cell|June 14, 2012
Tackling drought stress: receptor-like kinases present new approachesAlex Marshall, Reidunn B Aalen, Dominique Audenaert, et al.
Journal of Virology|February 4, 2025
Modeling suggests SARS-CoV-2 rebound after nirmatrelvir-ritonavir treatment is driven by target cell preservation coupled with incomplete viral clearanceTin Phan, Ruy M Ribeiro, Gregory E Edelstein, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 28, 2025
Comparative Outcomes of Babesiosis in Immunocompromised and Non-Immunocompromised Hosts: A Multicenter Cohort StudyLoukas Kakoullis, Carolyn D Alonso, Rebecca Burns, et al.
Pageof 45

Showing results (431-440 of 448) with videos related to

Sort By:
Pageof 45
Plant Physiology|April 8, 2021
Magnesium and calcium overaccumulate in the leaves of a schengen3 mutant of Brassica rapaThomas D Alcock, Catherine L Thomas, Seosamh Ó Lochlainn, et al.
The Journal of Antimicrobial Chemotherapy|October 14, 2017
Pharmacokinetics and safety results from the Phase 3 randomized, open-label, study of intravenous posaconazole in patients at risk of invasive fungal diseaseOliver A Cornely, Michael N Robertson, Shariq Haider, et al.
The Journal of Antimicrobial Chemotherapy|September 30, 2017
Pharmacokinetics and safety results from the Phase 3 randomized, open-label, study of intravenous posaconazole in patients at risk of invasive fungal diseaseOliver A Cornely, Michael N Robertson, Shariq Haider, et al.
New Microbes and New Infections|September 2, 2025
An open-label phase II trial of sotrovimab (VIR-7831) prophylaxis against COVID-19 infection in immunocompromised individuals with impaired SARS-CoV-2 humoral immunityIsabel H Gonzalez-Bocco, Rayven Frierson, Alyssa Cho, et al.
The Plant Cell|January 10, 2012
Analyzing lateral root development: how to move forwardIve De Smet, Philip J White, A Glyn Bengough, et al.
Annals of Internal Medicine|November 13, 2023
SARS-CoV-2 Virologic Rebound With Nirmatrelvir-Ritonavir Therapy : An Observational StudyGregory E Edelstein, Julie Boucau, Rockib Uddin, et al.
Medrxiv : the Preprint Server for Health Sciences|July 10, 2023
SARS-CoV-2 virologic rebound with nirmatrelvir-ritonavir therapyGregory E Edelstein, Julie Boucau, Rockib Uddin, et al.
The Plant Cell|June 14, 2012
Tackling drought stress: receptor-like kinases present new approachesAlex Marshall, Reidunn B Aalen, Dominique Audenaert, et al.
Journal of Virology|February 4, 2025
Modeling suggests SARS-CoV-2 rebound after nirmatrelvir-ritonavir treatment is driven by target cell preservation coupled with incomplete viral clearanceTin Phan, Ruy M Ribeiro, Gregory E Edelstein, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 28, 2025
Comparative Outcomes of Babesiosis in Immunocompromised and Non-Immunocompromised Hosts: A Multicenter Cohort StudyLoukas Kakoullis, Carolyn D Alonso, Rebecca Burns, et al.
Pageof 45